New data from Nordic market research firm DLIMI reveals that Danish sales of hospital medicine in January 2016 were 6% lower than hospital medicine sales in January 2015.
According to chief consultant Søren Beicker Sørensen, this corresponds to a decline in public expenditure of between 6% and 10%.
He stressed that the drop in spending means that the trend from third-quarter and fourth-quarter 2015 Is continuing, noting that this drop in spending should also be seen in the light of patent expiries for biological drugs which have led to greater competition on their prices.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze